NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Innate Pharma S.A. (IPHA) Stock Analysis

Innate Pharma S.A. (IPHA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IPHA

$2.08

−$0.03 (−1.42%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IPHA with… →

IPHA Key Statistics

As of Sep 4, 2026
Trading
Open
$2.10
Previous Close
$2.11
Day's Range
2.03–2.15
52-Week Range
1.17–2.71
Volume
9.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.88
Valuation
Market Cap
$232.34M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
25.80
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.64
Financials (FY)
Revenue (FY)
$2.79M−77.92%
Net Income (FY)
−$49.18M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
111.70M
1-Year Return
−0.76%
Dividend and dates
Earnings Date
September 17, 2026
Avg Volume
151.13K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IPHA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+18.86%
2025−4.89%
2024−34.29%
2023−24.93%
2022−18.20%
2021+11.49%
2020−36.49%
2019 (partial year)+6.45%

As of September 4, 2026.

IPHA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.79M−$49.18M−1764.5%
2024$12.62M−$49.47M−392.0%
2023$51.90M−$7.57M−14.6%
2022$49.58M−$58.10M−117.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.79M—−$53.43M−$49.18M−1764.5%
2024$12.62M—−$51.58M−$49.47M−392.0%
2023$51.90M—−$12.67M−$7.57M−14.6%
2022$49.58M—−$16.43M−$58.10M−117.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IPHA Valuation vs Biotechnology Median

Median of 656 stocks
MetricIPHABiotechnology medianvs median
P/S ratio25.8015.2669% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Innate Pharma S.A. (IPHA) is capitalised at $232.34M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 164 employees.

The most recent close on file for IPHA is $2.08, dated September 4, 2026. That is −$0.03 (−1.42%) against the previous close. Over the past 52 weeks the price has ranged from $1.17 to $2.71. The latest close sits 77.78% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.79M. That is −77.92% against the prior fiscal year, when revenue was $12.62M. The same year closed with a net loss of $49.18M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.64.

Across the 4 fiscal years on file, revenue moves from $49.58M in 2022 to $2.79M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 25.8 times revenue. On price-to-sales that is 69.04% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −0.76%. Across 5 years the annualized return works out at −19.49%. Beta against the wider market is reported at 0.88. Annualized volatility over the trailing 6 years is 91.16%.

Growth & Income

No dividend is on file for IPHA.

2026 is still running; the price is +18.86% year to date. The strongest complete calendar year on file is 2021 at +11.49%; the weakest is 2020 at −36.49%. Of the 6 complete calendar years on file, 1 finished higher.

Peer Comparison

Innate Pharma S.A. (IPHA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Innate Pharma S.A. IPHA $232.34M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Innate Pharma S.A. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Innate Pharma S.A.

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Visit website →